Gary Maharaj - SurModics CEO and President and Director
| SRDX Stock | USD 36.88 0.24 0.66% |
CEO
Mr. Gary R. Maharaj is President, Chief Executive Officer and Director of SurModics Inc. Prior to joining the Company, Mr. Maharaj served as President and Chief Executive Officer of Arizant Inc., a provider of patient temperature management systems in hospital operating rooms, from 2006 to 2010. Previously, Mr. Maharaj served in several senior level management positions for Augustine Medical, Inc. from 1996 to 2006, including Vice President of Marketing, and Vice President of Research and Development. During his 30 years in the medical device industry, Mr. Maharaj has also served in various management and research positions for the orthopedic implant and rehabilitation divisions of Smith Nephew, PLC. He was a director of NVE Corporationrationration, a public technology company since 2014, and serves as a member of the audit committee and as a member of the compensation committee. since 2010.
| Age | 62 |
| Tenure | 15 years |
| Address | 9924 West 74th Street, Eden Prairie, MN, United States, 55344-3523 |
| Phone | 952 500 7000 |
| Web | https://www.surmodics.com |
Gary Maharaj Latest Insider Activity
Tracking and analyzing the buying and selling activities of Gary Maharaj against SurModics stock is an integral part of due diligence when investing in SurModics. Gary Maharaj insider activity provides valuable insight into whether SurModics is net buyers or sellers over its current business cycle. Note, SurModics insiders must abide by specific rules, including filing SEC forms every time they buy or sell SurModics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Gary Maharaj over three months ago Disposition of 61017 shares by Gary Maharaj of SurModics at 33.2 subject to Rule 16b-3 | ||
Gary Maharaj over six months ago Acquisition by Gary Maharaj of 24356 shares of SurModics subject to Rule 16b-3 |
SurModics Management Efficiency
Return On Tangible Assets is likely to rise to -0.11 in 2025. Return On Capital Employed is likely to rise to -0.04 in 2025. At this time, SurModics' Other Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 60.7 M in 2025, whereas Total Assets are likely to drop slightly above 142.8 M in 2025. SurModics' management efficiency ratios could be used to measure how well SurModics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 12 records | CEO Age | ||
| Kathleen Skarvan | Electromed | 68 | |
| Glendon French | Pulmonx Corp | 62 | |
| Albert DaCosta | Paragon 28 | 52 | |
| Charles II | Apyx Medical | 59 | |
| Vladimir Makatsaria | LivaNova PLC | 52 | |
| Steven Williamson | Pulmonx Corp | 52 | |
| Mark Throdahl | Orthopediatrics Corp | 74 | |
| Massimo Calafiore | Orthofix Medical | 53 | |
| Damien McDonald | LivaNova PLC | 59 | |
| Joel Becker | Neuropace | 57 | |
| Joseph Dziedzic | Integer Holdings Corp | 57 | |
| Karen Zaderej | Axogen Inc | 63 | |
Management Performance
| Return On Equity | -0.0967 | ||||
| Return On Asset | -0.0066 |
SurModics Leadership Team
Elected by the shareholders, the SurModics' board of directors comprises two types of representatives: SurModics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SurModics. The board's role is to monitor SurModics' management team and ensure that shareholders' interests are well served. SurModics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SurModics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joel Suiter, Director Development | ||
| Timothy Arens, VP of Corporate Devel. and Strategy | ||
| Charles Olson, Sr. VP and General Manager of Medical Device | ||
| Gary Maharaj, CEO and President and Director | ||
| Joseph Stich, VP and General Manager of In-Vitro Diagnostics | ||
| Gordon JD, General Legal | ||
| Gordon Weber, General Legal | ||
| Teryl Sides, Senior Interventions | ||
| John Manders, Corporate Controller and Principal Accounting Officer | ||
| Gregg Sutton, Vice President - Research & Development |
SurModics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SurModics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0967 | ||||
| Return On Asset | -0.0066 | ||||
| Profit Margin | (0.09) % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 516.87 M | ||||
| Shares Outstanding | 14.29 M | ||||
| Shares Owned By Insiders | 3.38 % | ||||
| Shares Owned By Institutions | 84.36 % | ||||
| Number Of Shares Shorted | 347.95 K | ||||
| Price To Earning | 69.21 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Additional Tools for SurModics Stock Analysis
When running SurModics' price analysis, check to measure SurModics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SurModics is operating at the current time. Most of SurModics' value examination focuses on studying past and present price action to predict the probability of SurModics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SurModics' price. Additionally, you may evaluate how the addition of SurModics to your portfolios can decrease your overall portfolio volatility.